ID   MPIP3_HUMAN             Reviewed;         473 AA.
AC   P30307; D3DQB8; Q96PL3; Q9H168; Q9H2E8; Q9H2E9; Q9H2F1;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   10-MAY-2017, entry version 178.
DE   RecName: Full=M-phase inducer phosphatase 3;
DE            EC=3.1.3.48;
DE   AltName: Full=Dual specificity phosphatase Cdc25C;
GN   Name=CDC25C;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT CYS-70.
RX   PubMed=2195549; DOI=10.1073/pnas.87.13.5139;
RA   Sadhu K., Reed B.I., Richardson H., Russell P.;
RT   "Human homolog of fission yeast cdc25 mitotic inducer is predominantly
RT   expressed in G2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:5139-5143(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RX   PubMed=11078813;
RA   Bureik M., Rief N., Drescher R., Jungbluth A., Montenarh M.,
RA   Wagner P.;
RT   "An additional transcript of the cdc25C gene from A431 cells encodes a
RT   functional protein.";
RL   Int. J. Oncol. 17:1251-1258(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   CYS-70.
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 32-210 (ISOFORMS 2; 4 AND 5), AND
RP   VARIANT CYS-70.
RX   PubMed=11139144; DOI=10.1078/0171-9335-00115;
RA   Wegener S., Hampe W., Herrmann D., Schaller H.C.;
RT   "Alternative splicing in the regulatory region of the human
RT   phosphatases CDC25A and CDC25C.";
RL   Eur. J. Cell Biol. 79:810-815(2000).
RN   [7]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Colon carcinoma;
RX   PubMed=11304565; DOI=10.1038/labinvest.3780254;
RA   Hernandez S., Bessa X., Bea S., Hernandez L., Nadal A., Mallofre C.,
RA   Muntane J., Castells A., Fernandez P.L., Cardesa A., Campo E.;
RT   "Differential expression of cdc25 cell-cycle-activating phosphatases
RT   in human colorectal carcinoma.";
RL   Lab. Invest. 81:465-473(2001).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT THR-48; THR-67;
RP   SER-122; THR-130; SER-168 AND SER-214.
RX   PubMed=8119945;
RA   Strausfeld U., Fernandez A., Capony J.P., Girard F., Lautredou N.,
RA   Derancourt J., Labbe J.C., Lamb N.J.;
RT   "Activation of p34cdc2 protein kinase by microinjection of human
RT   cdc25C into mammalian cells. Requirement for prior phosphorylation of
RT   cdc25C by p34cdc2 on sites phosphorylated at mitosis.";
RL   J. Biol. Chem. 269:5989-6000(1994).
RN   [9]
RP   PHOSPHORYLATION BY PLK3.
RX   PubMed=10557092; DOI=10.1038/sj.onc.1202983;
RA   Ouyang B., Li W., Pan H., Meadows J., Hoffmann I., Dai W.;
RT   "The physical association and phosphorylation of Cdc25C protein
RT   phosphatase by Prk.";
RL   Oncogene 18:6029-6036(1999).
RN   [10]
RP   PHOSPHORYLATION BY PLK1.
RX   PubMed=11202906; DOI=10.1016/S0898-6568(00)00080-2;
RA   Roshak A.K., Capper E.A., Imburgia C., Fornwald J., Scott G.,
RA   Marshall L.A.;
RT   "The human polo-like kinase, PLK, regulates cdc2/cyclin B through
RT   phosphorylation and activation of the cdc25C phosphatase.";
RL   Cell. Signal. 12:405-411(2000).
RN   [11]
RP   PHOSPHORYLATION AT SER-216, AND INTERACTION WITH MAPK14 AND 14-3-3
RP   PROTEINS.
RX   PubMed=11333986; DOI=10.1038/35075107;
RA   Bulavin D.V., Higashimoto Y., Popoff I.J., Gaarde W.A., Basrur V.,
RA   Potapova O., Appella E., Fornace A.J. Jr.;
RT   "Initiation of a G2/M checkpoint after ultraviolet radiation requires
RT   p38 kinase.";
RL   Nature 411:102-107(2001).
RN   [12]
RP   INTERACTION WITH PLK1, PHOSPHORYLATION AT SER-129 AND THR-130, AND
RP   MUTAGENESIS OF SER-129 AND THR-130.
RX   PubMed=12595692; DOI=10.1126/science.1079079;
RA   Elia A.E., Cantley L.C., Yaffe M.B.;
RT   "Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to
RT   mitotic substrates.";
RL   Science 299:1228-1231(2003).
RN   [13]
RP   PHOSPHORYLATION AT SER-216.
RC   TISSUE=Testis;
RX   PubMed=15150265; DOI=10.1074/jbc.M404728200;
RA   Lu R., Niida H., Nakanishi M.;
RT   "Human SAD1 kinase is involved in UV-induced DNA damage checkpoint
RT   function.";
RL   J. Biol. Chem. 279:31164-31170(2004).
RN   [14]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-191 AND SER-198, AND
RP   MUTAGENESIS OF SER-191.
RX   PubMed=14968113; DOI=10.1038/sj.onc.1207425;
RA   Bahassi el M., Hennigan R.F., Myer D.L., Stambrook P.J.;
RT   "Cdc25C phosphorylation on serine 191 by Plk3 promotes its nuclear
RT   translocation.";
RL   Oncogene 23:2658-2663(2004).
RN   [15]
RP   INTERACTION WITH HIV-1 VPR, AND MUTAGENESIS OF GLU-352 AND LYS-359.
RX   PubMed=14972559; DOI=10.1016/j.virol.2003.10.007;
RA   Goh W.C., Manel N., Emerman M.;
RT   "The human immunodeficiency virus Vpr protein binds Cdc25C:
RT   implications for G2 arrest.";
RL   Virology 318:337-349(2004).
RN   [16]
RP   PHOSPHORYLATION AT SER-216 BY MAPKAPK2.
RX   PubMed=15629715; DOI=10.1016/j.molcel.2004.11.021;
RA   Manke I.A., Nguyen A., Lim D., Stewart M.Q., Elia A.E., Yaffe M.B.;
RT   "MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the
RT   G2/M transition and S phase progression in response to UV
RT   irradiation.";
RL   Mol. Cell 17:37-48(2005).
RN   [17]
RP   PHOSPHORYLATION BY PLK4.
RX   PubMed=18239451; DOI=10.4161/cc.7.4.5387;
RA   Bonni S., Ganuelas M.L., Petrinac S., Hudson J.W.;
RT   "Human Plk4 phosphorylates Cdc25C.";
RL   Cell Cycle 7:545-547(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64; SER-168 AND SER-472,
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-61 (ISOFORMS 4 AND 5),
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-38; THR-48; SER-57;
RP   SER-61; SER-64 AND THR-67, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-61; SER-64 AND THR-67,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20; SER-38 AND SER-216,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
CC   -!- FUNCTION: Functions as a dosage-dependent inducer in mitotic
CC       control. Tyrosine protein phosphatase required for progression of
CC       the cell cycle. When phosphorylated, highly effective in
CC       activating G2 cells into prophase. Directly dephosphorylates CDK1
CC       and activates its kinase activity. {ECO:0000269|PubMed:8119945}.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate.
CC   -!- SUBUNIT: Interacts with HIV-1 Vpr, thereby inactivating CDC25C
CC       phosphatase activity. Interacts with MAPK14 and 14-3-3 proteins.
CC       When phosphorylated on Ser-129 and/or Thr-130, interacts with
CC       PLK1. {ECO:0000269|PubMed:11333986, ECO:0000269|PubMed:12595692,
CC       ECO:0000269|PubMed:14972559}.
CC   -!- INTERACTION:
CC       P06493:CDK1; NbExp=2; IntAct=EBI-974439, EBI-444308;
CC       O14757:CHEK1; NbExp=2; IntAct=EBI-974439, EBI-974488;
CC       Q9Y250:LZTS1; NbExp=2; IntAct=EBI-974439, EBI-1216080;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14968113,
CC       ECO:0000269|PubMed:8119945}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=CDC25C1;
CC         IsoId=P30307-1; Sequence=Displayed;
CC       Name=2; Synonyms=CDC25C2;
CC         IsoId=P30307-2; Sequence=VSP_000864;
CC       Name=3; Synonyms=CDC25C3;
CC         IsoId=P30307-5; Sequence=Not described;
CC       Name=4; Synonyms=CDC25C4;
CC         IsoId=P30307-3; Sequence=VSP_000863;
CC         Note=Contains a phosphoserine at position 61.
CC         {ECO:0000244|PubMed:18691976};
CC       Name=5; Synonyms=CDC25C5, Cdc25Cdm;
CC         IsoId=P30307-4; Sequence=VSP_000863, VSP_000864;
CC         Note=Contains a phosphoserine at position 61.
CC         {ECO:0000244|PubMed:18691976};
CC   -!- DEVELOPMENTAL STAGE: Expressed predominantly in G2 phase.
CC   -!- PTM: Phosphorylated by CHEK1 and MAPK14 at Ser-216. This
CC       phosphorylation creates a binding site for 14-3-3 protein and
CC       inhibits the phosphatase. Phosphorylated by PLK4. Phosphorylated
CC       by PLK1, leading to activate the phosphatase activity.
CC       Phosphorylation by PLK3 at Ser-191 promotes nuclear translocation.
CC       Ser-198 is a minor phosphorylation site. Was initially reported to
CC       be phosphorylated by PLK3 at Ser-216 (PubMed:10557092). However,
CC       such phosphorylation by PLK3 was not confirmed by other groups.
CC       Phosphorylation at Thr-48, Thr-67, Ser-122, Thr-130, Ser-168 and
CC       Ser-214 occurs at G2 and G2-M transition and is probably catalyzed
CC       by CDK1. Ser-168 phosphorylation levels are lower than those at
CC       the other 5 CDK1 sites. Phosphorylation by CDK1 leads to increased
CC       activity. {ECO:0000269|PubMed:10557092,
CC       ECO:0000269|PubMed:11202906, ECO:0000269|PubMed:11333986,
CC       ECO:0000269|PubMed:14968113, ECO:0000269|PubMed:15150265,
CC       ECO:0000269|PubMed:15629715, ECO:0000269|PubMed:18239451,
CC       ECO:0000269|PubMed:8119945}.
CC   -!- SIMILARITY: Belongs to the MPI phosphatase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdc25c/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M34065; AAA35666.1; -; mRNA.
DR   EMBL; AJ304504; CAC19192.1; -; mRNA.
DR   EMBL; AY497474; AAR32098.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW62145.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW62149.1; -; Genomic_DNA.
DR   EMBL; BC019089; AAH19089.1; -; mRNA.
DR   EMBL; AF277723; AAG41885.1; -; mRNA.
DR   EMBL; AF277725; AAG41887.1; -; mRNA.
DR   EMBL; AF277726; AAG41888.1; -; mRNA.
DR   EMBL; AF312681; AAL26835.1; -; mRNA.
DR   CCDS; CCDS4202.1; -. [P30307-1]
DR   CCDS; CCDS4203.1; -. [P30307-4]
DR   PIR; I59168; A38874.
DR   RefSeq; NP_001274511.1; NM_001287582.1. [P30307-1]
DR   RefSeq; NP_001305027.1; NM_001318098.1.
DR   RefSeq; NP_001781.2; NM_001790.4. [P30307-1]
DR   RefSeq; NP_073720.1; NM_022809.3. [P30307-4]
DR   RefSeq; XP_011542064.1; XM_011543762.1. [P30307-4]
DR   UniGene; Hs.656; -.
DR   PDB; 2OJX; X-ray; 2.85 A; E=126-134.
DR   PDB; 3BZI; X-ray; 2.10 A; E=126-134.
DR   PDB; 3OP3; X-ray; 2.63 A; A=270-462.
DR   PDBsum; 2OJX; -.
DR   PDBsum; 3BZI; -.
DR   PDBsum; 3OP3; -.
DR   ProteinModelPortal; P30307; -.
DR   SMR; P30307; -.
DR   BioGrid; 107430; 37.
DR   DIP; DIP-24183N; -.
DR   IntAct; P30307; 10.
DR   MINT; MINT-86355; -.
DR   STRING; 9606.ENSP00000321656; -.
DR   BindingDB; P30307; -.
DR   ChEMBL; CHEMBL2378; -.
DR   DEPOD; P30307; -.
DR   iPTMnet; P30307; -.
DR   PhosphoSitePlus; P30307; -.
DR   BioMuta; CDC25C; -.
DR   DMDM; 116242631; -.
DR   PaxDb; P30307; -.
DR   PeptideAtlas; P30307; -.
DR   PRIDE; P30307; -.
DR   DNASU; 995; -.
DR   Ensembl; ENST00000323760; ENSP00000321656; ENSG00000158402. [P30307-1]
DR   Ensembl; ENST00000348983; ENSP00000345205; ENSG00000158402. [P30307-4]
DR   Ensembl; ENST00000415130; ENSP00000392631; ENSG00000158402. [P30307-4]
DR   Ensembl; ENST00000513970; ENSP00000424795; ENSG00000158402. [P30307-1]
DR   Ensembl; ENST00000514555; ENSP00000425470; ENSG00000158402. [P30307-2]
DR   GeneID; 995; -.
DR   KEGG; hsa:995; -.
DR   UCSC; uc003lcp.3; human. [P30307-1]
DR   CTD; 995; -.
DR   DisGeNET; 995; -.
DR   GeneCards; CDC25C; -.
DR   HGNC; HGNC:1727; CDC25C.
DR   HPA; CAB003800; -.
DR   HPA; HPA066991; -.
DR   MIM; 157680; gene.
DR   neXtProt; NX_P30307; -.
DR   OpenTargets; ENSG00000158402; -.
DR   PharmGKB; PA100; -.
DR   eggNOG; KOG3772; Eukaryota.
DR   eggNOG; COG5105; LUCA.
DR   GeneTree; ENSGT00390000018747; -.
DR   HOVERGEN; HBG052501; -.
DR   InParanoid; P30307; -.
DR   KO; K05867; -.
DR   OMA; TVSLCDI; -.
DR   OrthoDB; EOG091G0H0D; -.
DR   PhylomeDB; P30307; -.
DR   TreeFam; TF101056; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   Reactome; R-HSA-156711; Polo-like kinase mediated events.
DR   Reactome; R-HSA-157881; Cyclin B2 mediated events.
DR   Reactome; R-HSA-176187; Activation of ATR in response to replication stress.
DR   Reactome; R-HSA-5625740; RHO GTPases activate PKNs.
DR   Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest.
DR   Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain.
DR   Reactome; R-HSA-69273; Cyclin A/B1 associated events during G2/M transition.
DR   Reactome; R-HSA-75035; Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex.
DR   Reactome; R-HSA-8862803; Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models.
DR   SIGNOR; P30307; -.
DR   ChiTaRS; CDC25C; human.
DR   EvolutionaryTrace; P30307; -.
DR   GeneWiki; CDC25C; -.
DR   GenomeRNAi; 995; -.
DR   PRO; PR:P30307; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000158402; -.
DR   CleanEx; HS_CDC25C; -.
DR   ExpressionAtlas; P30307; baseline and differential.
DR   Genevisible; P30307; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0004721; F:phosphoprotein phosphatase activity; TAS:Reactome.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; NAS:UniProtKB.
DR   GO; GO:0050699; F:WW domain binding; IPI:BHF-UCL.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0008283; P:cell proliferation; TAS:UniProtKB.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; TAS:Reactome.
DR   GO; GO:0006260; P:DNA replication; TAS:Reactome.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IGI:UniProtKB.
DR   GO; GO:0007067; P:mitotic nuclear division; IEA:UniProtKB-KW.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:Reactome.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein serine/threonine kinase activity; TAS:UniProtKB.
DR   GO; GO:0007088; P:regulation of mitotic nuclear division; TAS:ProtInc.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 3.40.250.10; -; 1.
DR   InterPro; IPR000751; MPI_Phosphatase.
DR   InterPro; IPR001763; Rhodanese-like_dom.
DR   Pfam; PF06617; M-inducer_phosp; 1.
DR   Pfam; PF00581; Rhodanese; 1.
DR   PRINTS; PR00716; MPIPHPHTASE.
DR   SMART; SM00450; RHOD; 1.
DR   SUPFAM; SSF52821; SSF52821; 1.
DR   PROSITE; PS50206; RHODANESE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell cycle;
KW   Cell division; Complete proteome; Host-virus interaction; Hydrolase;
KW   Mitosis; Nucleus; Phosphoprotein; Polymorphism; Protein phosphatase;
KW   Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    473       M-phase inducer phosphatase 3.
FT                                /FTId=PRO_0000198647.
FT   DOMAIN      321    428       Rhodanese. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00173}.
FT   REGION      334    379       HIV-1 Vpr binding site.
FT   ACT_SITE    377    377       {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES      20     20       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      38     38       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      48     48       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000269|PubMed:8119945}.
FT   MOD_RES      57     57       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES      61     61       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES      64     64       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES      67     67       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000269|PubMed:8119945}.
FT   MOD_RES     122    122       Phosphoserine; by CDK1.
FT                                {ECO:0000305|PubMed:8119945}.
FT   MOD_RES     129    129       Phosphoserine.
FT                                {ECO:0000269|PubMed:12595692}.
FT   MOD_RES     130    130       Phosphothreonine.
FT                                {ECO:0000269|PubMed:12595692}.
FT   MOD_RES     168    168       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000269|PubMed:8119945}.
FT   MOD_RES     191    191       Phosphoserine; by PLK3.
FT                                {ECO:0000269|PubMed:14968113}.
FT   MOD_RES     198    198       Phosphoserine; by PLK3.
FT                                {ECO:0000269|PubMed:14968113}.
FT   MOD_RES     214    214       Phosphoserine; by CDK1.
FT                                {ECO:0000305|PubMed:8119945}.
FT   MOD_RES     216    216       Phosphoserine; by CHEK1, CHEK2, BRSK1 and
FT                                MAPK14. {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:11333986,
FT                                ECO:0000269|PubMed:15150265,
FT                                ECO:0000269|PubMed:15629715}.
FT   MOD_RES     472    472       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   VAR_SEQ      66    123       GTPKRCLDLSNLSSGEITATQLTTSADLDETGHLDSSGLQE
FT                                VHLAGMNHDQHLMKCSP -> SPGFFRTSGSAFSWD (in
FT                                isoform 4 and isoform 5).
FT                                {ECO:0000303|PubMed:11078813,
FT                                ECO:0000303|PubMed:11139144}.
FT                                /FTId=VSP_000863.
FT   VAR_SEQ     124    153       Missing (in isoform 2 and isoform 5).
FT                                {ECO:0000303|PubMed:11078813,
FT                                ECO:0000303|PubMed:11139144}.
FT                                /FTId=VSP_000864.
FT   VARIANT      14     14       S -> N (in dbSNP:rs11567959).
FT                                /FTId=VAR_027922.
FT   VARIANT      70     70       R -> C (in dbSNP:rs3734166).
FT                                {ECO:0000269|PubMed:11139144,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:2195549}.
FT                                /FTId=VAR_027923.
FT   VARIANT      78     78       S -> N (in dbSNP:rs11567962).
FT                                /FTId=VAR_027924.
FT   VARIANT     297    297       G -> R (in dbSNP:rs11567997).
FT                                /FTId=VAR_020146.
FT   MUTAGEN     129    129       S->V: Loss of phosphorylation. Severely
FT                                impairs PLK1-binding.
FT                                {ECO:0000269|PubMed:12595692}.
FT   MUTAGEN     130    130       T->A: Loss of phosphorylation. Severely
FT                                impairs PLK1-binding.
FT                                {ECO:0000269|PubMed:12595692}.
FT   MUTAGEN     191    191       S->A: Facilitates nuclear exclusion.
FT                                {ECO:0000269|PubMed:14968113}.
FT   MUTAGEN     191    191       S->D: Mimicks phosphorylation state,
FT                                leading to enhanced accumulation in the
FT                                nucleus. {ECO:0000269|PubMed:14968113}.
FT   MUTAGEN     352    352       E->K: Partial loss of HIV-1 Vpr binding.
FT                                {ECO:0000269|PubMed:14972559}.
FT   MUTAGEN     359    359       K->E: No effect on HIV-1 Vpr binding.
FT                                {ECO:0000269|PubMed:14972559}.
FT   STRAND      127    129       {ECO:0000244|PDB:3BZI}.
FT   STRAND      286    289       {ECO:0000244|PDB:3OP3}.
FT   STRAND      300    305       {ECO:0000244|PDB:3OP3}.
FT   HELIX       307    314       {ECO:0000244|PDB:3OP3}.
FT   TURN        315    321       {ECO:0000244|PDB:3OP3}.
FT   STRAND      322    329       {ECO:0000244|PDB:3OP3}.
FT   HELIX       333    337       {ECO:0000244|PDB:3OP3}.
FT   STRAND      339    341       {ECO:0000244|PDB:3OP3}.
FT   HELIX       350    357       {ECO:0000244|PDB:3OP3}.
FT   STRAND      369    376       {ECO:0000244|PDB:3OP3}.
FT   HELIX       384    397       {ECO:0000244|PDB:3OP3}.
FT   STRAND      409    412       {ECO:0000244|PDB:3OP3}.
FT   HELIX       415    419       {ECO:0000244|PDB:3OP3}.
FT   TURN        420    422       {ECO:0000244|PDB:3OP3}.
FT   HELIX       424    426       {ECO:0000244|PDB:3OP3}.
FT   STRAND      427    430       {ECO:0000244|PDB:3OP3}.
FT   STRAND      438    440       {ECO:0000244|PDB:3OP3}.
SQ   SEQUENCE   473 AA;  53365 MW;  0658A1F1B9B8996A CRC64;
     MSTELFSSTR EEGSSGSGPS FRSNQRKMLN LLLERDTSFT VCPDVPRTPV GKFLGDSANL
     SILSGGTPKR CLDLSNLSSG EITATQLTTS ADLDETGHLD SSGLQEVHLA GMNHDQHLMK
     CSPAQLLCST PNGLDRGHRK RDAMCSSSAN KENDNGNLVD SEMKYLGSPI TTVPKLDKNP
     NLGEDQAEEI SDELMEFSLK DQEAKVSRSG LYRSPSMPEN LNRPRLKQVE KFKDNTIPDK
     VKKKYFSGQG KLRKGLCLKK TVSLCDITIT QMLEEDSNQG HLIGDFSKVC ALPTVSGKHQ
     DLKYVNPETV AALLSGKFQG LIEKFYVIDC RYPYEYLGGH IQGALNLYSQ EELFNFFLKK
     PIVPLDTQKR IIIVFHCEFS SERGPRMCRC LREEDRSLNQ YPALYYPELY ILKGGYRDFF
     PEYMELCEPQ SYCPMHHQDH KTELLRCRSQ SKVQEGERQL REQIALLVKD MSP
//
